| Literature DB >> 32391806 |
Costantino Iadecola1, Marion S Buckwalter2, Josef Anrather1.
Abstract
Stroke is the second leading cause of death worldwide and a leading cause of disability. Most strokes are caused by occlusion of a major cerebral artery, and substantial advances have been made in elucidating how ischemia damages the brain. In particular, increasing evidence points to a double-edged role of the immune system in stroke pathophysiology. In the acute phase, innate immune cells invade brain and meninges and contribute to ischemic damage, but may also be protective. At the same time, danger signals released into the circulation by damaged brain cells lead to activation of systemic immunity, followed by profound immunodepression that promotes life-threatening infections. In the chronic phase, antigen presentation initiates an adaptive immune response targeted to the brain, which may underlie neuropsychiatric sequelae, a considerable cause of poststroke morbidity. Here, we briefly review these pathogenic processes and assess the potential therapeutic value of targeting immunity in human stroke.Entities:
Mesh:
Year: 2020 PMID: 32391806 PMCID: PMC7260029 DOI: 10.1172/JCI135530
Source DB: PubMed Journal: J Clin Invest ISSN: 0021-9738 Impact factor: 14.808